A citation-based method for searching scientific literature

Young Shin Cho, Julian R Levell, Gang Liu, Thomas Caferro, James Sutton, Cynthia M Shafer, Abran Costales, James R Manning, Qian Zhao, Martin Sendzik, Michael Shultz, Gregg Chenail, Julia Dooley, Brian Villalba, Ali Farsidjani, Jinyun Chen, Raviraj Kulathila, Xiaoling Xie, Stephanie Dodd, Ty Gould, Guiqing Liang, Tycho Heimbach, Kelly Slocum, Brant Firestone, Minying Pu, Raymond Pagliarini, Joseph D Growney. ACS Med Chem Lett 2017
Times Cited: 59







List of co-cited articles
721 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
62

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
52

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
52

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Janeta Popovici-Muller, René M Lemieux, Erin Artin, Jeffrey O Saunders, Francesco G Salituro, Jeremy Travins, Giovanni Cianchetta, Zhenwei Cai, Ding Zhou, Dawei Cui,[...]. ACS Med Chem Lett 2018
168
52

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010
45

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
42

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
42

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Katharine Yen, Jeremy Travins, Fang Wang, Muriel D David, Erin Artin, Kimberly Straley, Anil Padyana, Stefan Gross, Byron DeLaBarre, Erica Tobin,[...]. Cancer Discov 2017
237
42

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
40

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013
794
40

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Stefan Pusch, Sonja Krausert, Viktoria Fischer, Jörg Balss, Martina Ott, Daniel Schrimpf, David Capper, Felix Sahm, Jessica Eisel, Ann-Christin Beck,[...]. Acta Neuropathol 2017
108
40

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, S Kaulfuss, O Panknin, K Zimmermann, L Toschi,[...]. Leukemia 2017
77
38

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
Rasheduzzaman Chowdhury, Kar Kheng Yeoh, Ya-Min Tian, Lars Hillringhaus, Eleanor A Bagg, Nathan R Rose, Ivanhoe K H Leung, Xuan S Li, Esther C Y Woon, Ming Yang,[...]. EMBO Rep 2011
670
37

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Ujunwa C Okoye-Okafor, Boris Bartholdy, Jessy Cartier, Enoch N Gao, Beth Pietrak, Alan R Rendina, Cynthia Rominger, Chad Quinn, Angela Smallwood, Kenneth J Wiggall,[...]. Nat Chem Biol 2015
109
35

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser,[...]. Science 2013
576
35


Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn,[...]. Blood 2017
788
32

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Justin A Caravella, Jian Lin, R Bruce Diebold, Ann-Marie Campbell, Anna Ericsson, Gary Gustafson, Zhongguo Wang, Jennifer Castro, Andrea Clarke, Deepali Gotur,[...]. J Med Chem 2020
36
52

Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
Gejing Deng, Junqing Shen, Ming Yin, Jessica McManus, Magali Mathieu, Patricia Gee, Timothy He, Chaomei Shi, Olivier Bedel, Larry R McLean,[...]. J Biol Chem 2015
87
30

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018
691
30

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.
Janeta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, Jeremy M Travins, Shunqi Yan, Fang Zhao, Stefan Gross, Lenny Dang, Katharine E Yen, Hua Yang,[...]. ACS Med Chem Lett 2012
141
27

Recurring mutations found by sequencing an acute myeloid leukemia genome.
Elaine R Mardis, Li Ding, David J Dooling, David E Larson, Michael D McLellan, Ken Chen, Daniel C Koboldt, Robert S Fulton, Kim D Delehaunty, Sean D McGrath,[...]. N Engl J Med 2009
27

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Andrew M Intlekofer, Alan H Shih, Bo Wang, Abbas Nazir, Ariën S Rustenburg, Steven K Albanese, Minal Patel, Christopher Famulare, Fabian M Correa, Naofumi Takemoto,[...]. Nature 2018
146
27

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
M Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, Stephen Damato, Dina Halai, Fitim Berisha, Robin Pollock, Paul O'Donnell, Anita Grigoriadis, Tim Diss,[...]. J Pathol 2011
622
25

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity.
Xiang Xu, Jingyue Zhao, Zhen Xu, Baozhen Peng, Qiuhua Huang, Eddy Arnold, Jianping Ding. J Biol Chem 2004
266
23

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.
Julian R Levell, Thomas Caferro, Gregg Chenail, Ina Dix, Julia Dooley, Brant Firestone, Pascal D Fortin, John Giraldes, Ty Gould, Joseph D Growney,[...]. ACS Med Chem Lett 2016
23
56

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Darrell R Borger, Kenneth K Tanabe, Kenneth C Fan, Hector U Lopez, Valeria R Fantin, Kimberly S Straley, David P Schenkein, Aram F Hezel, Marek Ancukiewicz, Hannah M Liebman,[...]. Oncologist 2012
497
22

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
James J Harding, Maeve A Lowery, Alan H Shih, Juan M Schvartzman, Shengqi Hou, Christopher Famulare, Minal Patel, Mikhail Roshal, Richard K Do, Ahmet Zehir,[...]. Cancer Discov 2018
89
22

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S Modrek, Dimitris G Placantonakis. Front Oncol 2019
126
22

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Shimin Zhao, Yan Lin, Wei Xu, Wenqing Jiang, Zhengyu Zha, Pu Wang, Wei Yu, Zhiqiang Li, Lingling Gong, Yingjie Peng,[...]. Science 2009
838
20

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Zenon Konteatis, Erin Artin, Brandon Nicolay, Kimberly Straley, Anil K Padyana, Lei Jin, Yue Chen, Rohini Narayaraswamy, Shuilong Tong, Feng Wang,[...]. ACS Med Chem Lett 2020
43
27

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Julie-Aurore Losman, Ryan E Looper, Peppi Koivunen, Sungwoo Lee, Rebekka K Schneider, Christine McMahon, Glenn S Cowley, David E Root, Benjamin L Ebert, William G Kaelin. Science 2013
494
18

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Steven M Chan, Daniel Thomas, M Ryan Corces-Zimmerman, Seethu Xavy, Suchita Rastogi, Wan-Jen Hong, Feifei Zhao, Bruno C Medeiros, David A Tyvoll, Ravindra Majeti. Nat Med 2015
345
18

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Kensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, Shota Tanaka, Franziska Loebel, Nina Lelic, Dmitri Wiederschain, Olivier Bedel, Gejing Deng, Bailin Zhang,[...]. Cancer Cell 2015
230
18

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Peter Paschka, Richard F Schlenk, Verena I Gaidzik, Marianne Habdank, Jan Krönke, Lars Bullinger, Daniela Späth, Sabine Kayser, Manuela Zucknick, Katharina Götze,[...]. J Clin Oncol 2010
579
18

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward,[...]. Nature 2012
18

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick,[...]. Acta Neuropathol 2009
801
18

Enasidenib: First Global Approval.
Esther S Kim. Drugs 2017
74
16


Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Stefan Gross, Rob A Cairns, Mark D Minden, Edward M Driggers, Mark A Bittinger, Hyun Gyung Jang, Masato Sasaki, Shengfang Jin, David P Schenkein, Shinsan M Su,[...]. J Exp Med 2010
531
16

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Michael D Amatangelo, Lynn Quek, Alan Shih, Eytan M Stein, Mikhail Roshal, Muriel D David, Benoit Marteyn, Noushin Rahnamay Farnoud, Stephane de Botton, Olivier A Bernard,[...]. Blood 2017
227
16

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
Daniel J Urban, Natalia J Martinez, Mindy I Davis, Kyle R Brimacombe, Dorian M Cheff, Tobie D Lee, Mark J Henderson, Steven A Titus, Rajan Pragani, Jason M Rohde,[...]. Sci Rep 2017
35
28

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Saman Abbas, Sanne Lugthart, François G Kavelaars, Anita Schelen, Jasper E Koenders, Annelieke Zeilemaker, Wim J L van Putten, Anita W Rijneveld, Bob Löwenberg, Peter J M Valk. Blood 2010
272
15

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Hui Yang, Dan Ye, Kun-Liang Guan, Yue Xiong. Clin Cancer Res 2012
241
15

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Sevin Turcan, Armida W M Fabius, Alexandra Borodovsky, Alicia Pedraza, Cameron Brennan, Jason Huse, Agnes Viale, Gregory J Riggins, Timothy A Chan. Oncotarget 2013
159
15

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
Masato Sasaki, Christiane B Knobbe, Momoe Itsumi, Andrew J Elia, Isaac S Harris, Iok In Christine Chio, Rob A Cairns, Susan McCracken, Andrew Wakeham, Jillian Haight,[...]. Genes Dev 2012
204
15

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Houtan Noushmehr, Daniel J Weisenberger, Kristin Diefes, Heidi S Phillips, Kanan Pujara, Benjamin P Berman, Fei Pan, Christopher E Pelloski, Erik P Sulman, Krishna P Bhat,[...]. Cancer Cell 2010
15

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.
Andrew Kernytsky, Fang Wang, Erica Hansen, Stefanie Schalm, Kimberly Straley, Camelia Gliser, Hua Yang, Jeremy Travins, Stuart Murray, Marion Dorsch,[...]. Blood 2015
114
15


Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Xiaoling Xie, Daniel Baird, Kimberly Bowen, Vladimir Capka, Jinyun Chen, Gregg Chenail, YoungShin Cho, Julia Dooley, Ali Farsidjani, Pascal Fortin,[...]. Structure 2017
35
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.